Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Remote care trial offers hope for MND patients struggling to reach specialists

NCT ID NCT02464748

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a telehealth system could help people with motor neurone disease (MND) receive specialist care from home, avoiding long trips to the clinic. It involved 40 patients and their caregivers, with half using the system for up to 18 months. The goal was to see if this approach is practical and acceptable, not to cure the disease. Results will guide future larger trials on cost-effectiveness and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

77 people

The number who actually took part.

Start date

Sep 2014

Finished

Apr 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patient Inclusion Criteria: * Patients aged 18 years or over who have attended the MND clinic at the Royal Hallamshire Hospital, Sheffield. * Patients with amyotrophic lateral sclerosis diagnosed by a consultant neurologist with symptom onset within the last three years. o Or * Patients with amyotrophic lateral sclerosis, primary muscular atrophy or progressive lateral sclerosis diagnosed by a consultant neurologist with a deterioration in their condition as evidenced by a deterioration in the ALS functional rating score (ALSFRS-R) by at least two points during the previous 18 months. * Live within 120 minute drive from Sheffield Patient Exclusion Criteria: * Patients attend another MND care centre in the UK. * Significant impairment in decision making capacity preventing informed consent by the subject due to a major mental disorder including fronto-temporal dementia. * Patient unable to use the TiM system due to physical, intellectual or language difficulties and unwilling to permit carer to operate it on their behalf. Patients will be asked to complete two questions used within the TiM system, with, or without the help to their carer to verify their ability to use the system. * The patient has no eligible informal carer willing to participate in the trial * Insufficient mobile telephone reception in the patients' home to use the TiM system. * Any other major impairment that may affect their ability to participate in the study Carer inclusion criteria * Age 18 years or older * Person identified by the patient as the major provider of informal care (emotional and/or practical support) to the patient and provides more than one hour per week of unpaid care * Carer willing to allow data they provide during the trial to be shared by the research team with their own doctor in the event of serious clinical need. Carer exclusion criteria * Significant decision making capacity preventing informed consent due to a major mental disorder. * Carer unable to use the TiM system due to physical, intellectual or language difficulties. Carers will be asked to complete two questions used within the TiM system to verify their ability to use the system. * Inability to participate in the study due to other major physical or mental illness or language difficulties. * Professional carers receiving direct payment for their services.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sheffield Institute for Translational Neurosciences

    Sheffield, S10 2HQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.